Target intelligence / Profile preview

HIV Fusion Inhibitor (None)

Target: None
Molecular classification: Antiviral, Antiretroviral, Peptide

Overview

Fusion inhibitors are a class of antiviral drugs that prevent viruses, most notably HIV, from entering host cells. They achieve this by blocking the fusion of the viral envelope with the host cell membrane, thereby inhibiting a critical step in the viral entry process. They target the viral protein gp41, preventing it from mediating membrane fusion.

Mechanism of action

Blocks conformational changes and fusion between viral and host cell membranes, preventing viral entry.

Biological functions

Viral entry inhibitiongp41 inhibitionMembrane fusion inhibition

Disease associations

HIV infection

Safety considerations

Injection site reactionsGastrointestinal symptomsFatigueDevelopment of resistance

Interacting drugs

Enfuvirtide (Fuzeon/T20)

Beyond the preview

Go deeper on HIV Fusion Inhibitor (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV Fusion Inhibitor (None).

Explore the full profile